MwanzoORX • STO
add
Orexo AB
Bei iliyotangulia
kr 40.80
Bei za siku
kr 37.40 - kr 41.30
Bei za mwaka
kr 9.18 - kr 43.40
Thamani ya kampuni katika soko
1.32B SEK
Wastani wa hisa zilizouzwa
elfu 97.68
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
STO
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (SEK) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 118.20M | -23.25% |
Matumizi ya uendeshaji wa biashara | 128.10M | -18.09% |
Mapato halisi | -39.80M | -10.86% |
Kiwango cha faida halisi | -33.67 | -44.44% |
Mapato kwa kila hisa | -1.15 | -10.58% |
EBITDA | -6.90M | -428.57% |
Asilimia ya kodi ya mapato | -17.40% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (SEK) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 121.30M | -13.17% |
Jumla ya mali | 533.40M | -31.02% |
Jumla ya dhima | 730.40M | -2.50% |
Jumla ya hisa | -197.00M | — |
hisa zilizosalia | 34.71M | — |
Uwiano wa bei na thamani | -7.18 | — |
Faida inayotokana na mali | -8.61% | — |
Faida inayotokana mtaji | -14.73% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (SEK) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -39.80M | -10.86% |
Pesa kutokana na shughuli | elfu -700.00 | 89.23% |
Pesa kutokana na uwekezaji | — | — |
Pesa kutokana na ufadhili | 4.50M | 109.38% |
Mabadiliko halisi ya pesa taslimu | 2.20M | 103.77% |
Mtiririko huru wa pesa | 36.26M | 894.79% |
Kuhusu
Orexo is a Swedish pharmaceutical company that develops improved pharmaceuticals based on innovative formulation technologies that meet large medical needs. Through presence its in the US market, drugs and digital therapies are commercialized to treat opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with partners. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1995
Tovuti
Wafanyakazi
110
